JP4802251B2 - Health food composition made mainly of tahibo, champignon and mulberry leaves - Google Patents
Health food composition made mainly of tahibo, champignon and mulberry leaves Download PDFInfo
- Publication number
- JP4802251B2 JP4802251B2 JP2009010890A JP2009010890A JP4802251B2 JP 4802251 B2 JP4802251 B2 JP 4802251B2 JP 2009010890 A JP2009010890 A JP 2009010890A JP 2009010890 A JP2009010890 A JP 2009010890A JP 4802251 B2 JP4802251 B2 JP 4802251B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- champignon
- tahibo
- powder
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000001674 Agaricus brunnescens Nutrition 0.000 title claims description 69
- 244000251953 Agaricus brunnescens Species 0.000 title claims description 68
- 240000000249 Morus alba Species 0.000 title claims description 53
- 235000008708 Morus alba Nutrition 0.000 title claims description 53
- 235000013402 health food Nutrition 0.000 title claims description 12
- 239000000203 mixture Substances 0.000 title claims description 12
- 239000000843 powder Substances 0.000 claims description 35
- 239000002361 compost Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 5
- 240000000111 Saccharum officinarum Species 0.000 claims description 5
- 235000007201 Saccharum officinarum Nutrition 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000011777 magnesium Substances 0.000 description 8
- 229910052749 magnesium Inorganic materials 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 229910052793 cadmium Inorganic materials 0.000 description 5
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 3
- 235000019645 odor Nutrition 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019737 Animal fat Nutrition 0.000 description 2
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 239000010233 Taheebo Substances 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000009264 composting Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 235000003563 vegetarian diet Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Description
本発明は、タヒボ、シャンピニオン及び桑の葉を主原料にして製造された健康食品組成物に関するものである。したがって、本発明の健康食品組成物には自然にタヒボ、シャンピニオン及び桑の葉の成分がすべて均一に含有されている。 The present invention relates to a health food composition produced using tahibo, champignon and mulberry leaves as main raw materials. Accordingly, the health food composition of the present invention naturally contains all components of tahibo, champignon and mulberry leaves uniformly.
我々人間の健康状態は食べ物と密接な関係を持っている。
1970年代後半から所得向上に伴って食生活が西欧化されながら肉食が急速に増えながら、その間菜食を主にして来た過去にはあまりなかった各種成人病が急激に増加して、これらは社会問題にまで頭をもたげるようになった。すなわち、動物性脂肪食品や加工食品、インスタント食品及び各種食品添加物の摂取量が急増したので、腸内環境が悪くなるようになり、その結果平均寿命が大きく増えたにもかかわらず、人間本来の免疫力が低下して肥満、高血圧、糖尿、高脂血症など各種疾病にかかりやすくなった。
その結果、食生活に対する反省と共に健康に対する関心がいつより高くなり、これによって成人病を予防することができる健康食品に対する要求も大きく増えている。
We human health is closely related to food.
From the latter half of the 1970s, dietary habits have become westernized as incomes have increased, and meat diets have increased rapidly. Meanwhile, various adult diseases that have been mainly based on vegetarian diets have increased rapidly. I began to raise my head to the problem. In other words, the intake of animal fat foods, processed foods, instant foods and various food additives has increased rapidly, and the intestinal environment has deteriorated, resulting in a significant increase in life expectancy. As a result, the immunity of the patient decreased, making it more susceptible to various diseases such as obesity, hypertension, diabetes and hyperlipidemia.
As a result, there is a growing interest in health as well as reflections on dietary habits, which greatly increases the demand for health foods that can prevent adult diseases.
本発明は、タヒボ粉末、シャンピニオン粉末、桑の葉粉末を配合して製造された健康食品組成物を提供することにその目的がある。 An object of the present invention is to provide a health food composition produced by blending tahibo powder, champignon powder, and mulberry leaf powder.
本発明は、タヒボ粉末とシャンピニオン粉末及び桑の葉粉末を主原料にして製造された健康食品組成物に関するものであり、動物性脂肪食品の過多摂取による栄養過剰で社会問題になっているメタボリックシンドロームの改善とダイエットに大きい効果がある健康食品組成物に関するものである。 TECHNICAL FIELD The present invention relates to a health food composition produced mainly from tahibo powder, champignon powder, and mulberry leaf powder, and is a metabolic syndrome that has become a social problem due to overnutrition due to excessive intake of animal fat foods. It is related with the health food composition which has the big effect on improvement and diet.
前記目的は、タヒボ粉末20〜50重量部とシャンピニオン粉末20〜50重量部及び桑の葉粉末20〜50重量部を配合して製造されることによって達成される。 The object is achieved by blending 20-50 parts by weight of tahibo powder, 20-50 parts by weight of champignon powder and 20-50 parts by weight of mulberry leaf powder.
望ましくは、前記シャンピニオン粉末は、砂糖黍を搾った後残った残物または豆を搾った後残った残物を60〜90日間堆肥を生産する段階;
前記堆肥にシャンピニオン菌を注入して30〜50日間培養する段階;
前記培養されたシャンピニオンを採取して水で洗滌した後2〜5cm大きさで切断する段階;
前記大きさで切断したシャンピニオンを乾燥器に移送して、45〜55℃に8〜12時間乾燥させる段階;及び
前記乾燥したシャンピニオンを粉砕機に移送して、1.5mmの粉末に粉碎する段階;を経って製造されたことを特徴とする。
Preferably, the champignon powder is produced by composting a residue left after squeezing sugar cane or a residue left after squeezing beans for 60 to 90 days;
Injecting champignon into the compost and culturing for 30-50 days;
Collecting the cultured champignon, washing it with water and then cutting it to a size of 2-5 cm;
Transferring the champignon cut in the size to a dryer and drying it at 45 to 55 ° C. for 8 to 12 hours; and transferring the dried champignon to a pulverizer and pulverizing it into a powder of 1.5 mm It is characterized by being manufactured through;
本発明の健康食品組成物には、タヒボ、シャンピニオン及び桑の葉の成分がすべて均等に含有されているので、倦まず弛まず服用すれば口臭、体臭及び老人臭を予防することができるし、また糖尿病、高血圧、高脂血症、肥満など成人病の予防と消化浣腸症を予防するのに大きい役割をすることはもちろん、抗菌能力及び免疫力を増進させることができる。 In the health food composition of the present invention, all components of tahibo, champignon and mulberry leaves are contained evenly, so if you do not take it loose, you can prevent bad breath, body odor and old man odor, In addition, it can play a major role in preventing adult diseases such as diabetes, hypertension, hyperlipidemia, obesity and digestive enema, as well as enhancing antibacterial ability and immunity.
本発明は、タヒボ粉末、シャンピニオン粉末、桑の葉粉末を配合して製造された健康食品組成物に関するものである。 The present invention relates to a health food composition produced by blending tahibo powder, champignon powder, and mulberry leaf powder.
タヒボ(Taheebo)は、南米アマゾンに自生する木として現地では奇蹟の薬木と呼ばれている。タヒボには、殺菌力があって樹木には虫も付かないで、かびも生えないと言う。 Taheebo is locally known as a miracle medicinal tree that grows naturally in the South American Amazon. Tahibo says that it has a bactericidal power and does not have insects on the tree, nor does it grow mold.
タヒボの薬理作用としては、新陳代謝を活発にして、解毒、発汗、血液浄化及び血液循環促進、角質化された肌細胞の入れ替えを促進、新鮮な血液生産、脂肪吸収度と細胞活動の最適条件提示、老化防止、排尿促進、糖尿予防及び治療などに効果があるものとして知られている。 Tahivo's pharmacological actions include active metabolism, promotion of detoxification, sweating, blood purification and blood circulation, replacement of keratinized skin cells, fresh blood production, presentation of optimal conditions for fat absorption and cellular activity It is known to be effective in preventing aging, promoting urination, preventing and treating diabetes.
本発明では、タヒボ粉末20〜50重量部を配合した。 In the present invention, 20 to 50 parts by weight of tahibo powder is blended.
シャンピニオン(Shampinion)は、西洋きのこの一種であり、腸内環境において善菌をふやして、悪菌を減らす作用をして、腸内及び血液中の有害悪臭物質を中和させる能力があって、悪臭など各種においを除去するのに効果がある。 Champignon (Shampinion) is a kind of western mushroom, which has the ability to neutralize harmful malodorous substances in the intestines and blood by acting to reduce good bacteria by increasing good bacteria in the intestinal environment, It is effective in removing various odors such as bad odors.
シャンピニオン種菌を培養する菌床は、砂糖黍を搾った後残った残物または豆を搾った後残った残物を原料にして製造した。 The fungal bed for culturing the champignon inoculum was produced using a residue remaining after squeezing sugar cane or a residue remaining after squeezing beans.
シャンピニオン粉末を製造する工程は次のようである。 The process for producing champignon powder is as follows.
まず、砂糖黍を搾った後残った残物または豆を搾った後残った残物を60〜90日間堆肥を生産した後、前記堆肥にシャンピニオン菌を注入して30〜50日間培養する。引き続き、成熟されたシャンピニオンを採取して水で洗滌した後2〜5cm大きさで切断する。前記大きさで切断したシャンピニオンを乾燥器に移送して45〜55℃で8〜12時間乾燥させる。前記乾燥したシャンピニオンを粉砕機に移送して1.5mmの粉末に粉碎する。 First, compost is produced for 60 to 90 days from the residue remaining after squeezing sugar cane or the bean, and then champignon bacteria are injected into the compost and cultured for 30 to 50 days. Subsequently, the mature champignon is collected, washed with water, and then cut to a size of 2 to 5 cm. The champignon cut in the above size is transferred to a dryer and dried at 45-55 ° C. for 8-12 hours. The dried champignon is transferred to a pulverizer and ground into a 1.5 mm powder.
本発明では、シャンピニオン粉末20〜50重量部を配合した。 In the present invention, 20 to 50 parts by weight of champignon powder was blended.
桑の葉は、一言で成人病の総合予防剤であると同時に治療剤として相当な機能を持っている。 Mulberry leaves are a comprehensive preventive agent for adult diseases, and at the same time have a considerable function as a therapeutic agent.
桑の葉には、グルコシド、ビタミンC、B1、B2など100余種類以上の良い成分が含まれている。桑の葉は、タンパク質含量が葉のうちで最も高い。それだけではなく、桑の葉にはミネラルが豊かに入っていて、各種ビタミン、アミノ酸、繊維素が豊かに入っている。特に、桑の葉特有の成分である1-デオキシノジリマイシン(DNJ、deoxynojirimycin)を含んでいて、糖分を分解する酵素と特に急激な血糖量上昇を抑制する。また、桑の葉の内には脳内の血液循環をよくして、コレステロールを除去して老人性痴ほうを予防してくれるセリンとタイロシン成分がそれぞれ1.2%と0.8%入っている。 Mulberry leaves contain over 100 kinds of good ingredients such as glucoside, vitamins C, B1, and B2. Mulberry leaves have the highest protein content of the leaves. Not only that, mulberry leaves are rich in minerals, rich in various vitamins, amino acids, and fiber. In particular, it contains 1-deoxynojirimycin (DNJ, deoxynojirimycin), a component unique to mulberry leaves, and suppresses an enzyme that degrades sugar and a particularly rapid increase in blood glucose level. The mulberry leaves contain 1.2% and 0.8% serine and tylosin components, respectively, that improve blood circulation in the brain and remove cholesterol to prevent senile dementia. .
これ以外にも血圧を下げてくれる成分(ギャバ(GABA))、脳血管を丈夫にさせてくれる成分(ルチン)、そして血管に付いている油のかたまりをなくしてくれる作用、動脈硬化を無くしてくれる作用が明かにされている。 Other ingredients that lower blood pressure (GABA), ingredients that make cerebral blood vessels strong (rutin), and action that eliminates the clumps of oil attached to blood vessels, eliminate arteriosclerosis The action is clarified.
本発明では、桑の葉粉末20〜50重量部を配合した。 In the present invention, 20 to 50 parts by weight of mulberry leaf powder was blended.
したがって、本発明の健康食品組成物は、タヒボ粉末20〜50重量部、シャンピニオン粉末20〜50重量部、桑の葉粉末20〜50重量部を配合して製造される。 Therefore, the health food composition of the present invention is produced by blending 20-50 parts by weight of tahibo powder, 20-50 parts by weight of champignon powder, and 20-50 parts by weight of mulberry leaf powder.
1.生後6週齢の鼠を何も投与しないControl群、桑の葉だけ投与する桑の葉群、タヒボだけ投与するタヒボ群、シャンピニオンだけ投与するシャンピニオン群及びタヒボ・シャンピニオン・桑の葉を同一割合で投与する配合群で分類して、3週間隔日で所定物質を経口投与した後、血液を採取して抗酸化作用を測定した。 1. Control group that does not administer any 6-week old pupae, mulberry leaves group that administers only mulberry leaves, tahibo group that administers only tahibo, champignon group that administers only champignon and tahibo champignon mulberry leaves in the same ratio After the oral administration of a predetermined substance at intervals of 3 weeks, blood was collected and the antioxidant action was measured.
一方、60日間隔日で所定物質を経口投与した後、血液から尿素、乳酸、アンモニア濃度を、小便から金属元素の濃度を液体クロマトグラフィー(Chromatography)で検査して解毒効果を測定した。 On the other hand, after a predetermined substance was orally administered every 60 days, the concentration of urea, lactic acid and ammonia from blood and the concentration of metal elements from urine were examined by liquid chromatography to measure the detoxification effect.
又採取した血液を遠心分離して得た血清に対してルミノール(Luminol)測定とSOD活性度を測定して抗酸化作用に対する結果を得たし、血液を遠心分離して得た血清と小便(尿)を液体クロマトグラフィーで検査して解毒効果を測定した。 In addition, luminol (Luminol) measurement and SOD activity were measured on the serum obtained by centrifuging the collected blood to obtain an antioxidative effect, and the serum obtained by centrifuging the blood and urine ( Urine) was examined by liquid chromatography to determine the detoxification effect.
2.抗酸化効果
2-1.ルミノール測定結果
縦軸に測定した発光強度を示して、投与60日後のControl群、桑の葉群、タヒボ群、シャンピニオン群及び配合群の血清においてのペルオキシラディカル(Peroxy Radical)に対するスカベンジング(Scarvenging)作用の結果を図1に示した。
図1で見るところのように、Control群の発光強度と比べて桑の葉群、タヒボ群、シャンピニオン群、特に配合群の発光強度減少が著しかった。したがって、すべての投与群、特に配合群にペルオキシラディカルスカベンジング作用を期待することができることが分かる。
2. Antioxidant effect 2-1. Luminol measurement results show the luminescence intensity measured on the vertical axis, and scavenging action against peroxyradical in the serum of Control group, Mulberry leaf group, Tahibo group, Champignon group and
As can be seen from FIG. 1, the emission intensity of the mulberry leaves group, the tahibo group, the champignon group, particularly the combination group, was significantly lower than the emission intensity of the Control group. Therefore, it can be seen that peroxyradial scavenging action can be expected in all administration groups, particularly in the combination group.
2-2.SOD活性度
縦軸に測定したSOD活性度(%)を示して、投与60日後のControl群、桑の葉群、タヒボ群、シャンピニオン群及び配合群の血清においてのラディカルに対する抗酸化作用の結果を図2に示した。
図2で見るところのように、Control群のSOD活性度と比べて桑の葉群、タヒボ群、シャンピニオン群、特に配合群のSOD活性度増加が著しかった。したがって、すべての投与群に対する抗酸化作用を期待することができるし、特に配合群には抗酸化作用に相乗効果があることが分かる。
2-2. The SOD activity (%) measured on the vertical axis of the SOD activity indicates the antioxidative effect on radicals in the serum of the Control group, Mulberry leaf group, Tahibo group, Champignon group and
As seen in FIG. 2, the increase in SOD activity in the mulberry leaf group, the tahibo group, the champignon group, particularly the combination group, was significant compared with the SOD activity in the Control group. Therefore, it can be expected that the anti-oxidation effect for all the administration groups, and in particular, the combination group has a synergistic effect on the anti-oxidation effect.
2-3.血中の尿素、乳酸、アンモニアなどの濃度
2-3-1.血中の尿素濃度
投与60日後のControl群、桑の葉群、タヒボ群、シャンピニオン群及び配合群の血中の尿素濃度の結果を図3に示した。
図3で見るところのようにControl群と比べて桑の葉群、タヒボ群、シャンピニオン群の血中の尿素濃度低下が認められたし、特に配合群の血中の尿素濃度低下が著しかった。
2-3. Concentrations of urea, lactic acid, ammonia, etc. in the blood 2-3-1. FIG. 3 shows the blood urea concentration results of the Control group, the mulberry leaf group, the tahibo group, the champignon group, and the
As shown in FIG. 3, a decrease in blood urea concentration was observed in the mulberry leaf group, the tahibo group, and the champignon group as compared with the Control group, and in particular, the decrease in the blood urea concentration in the combination group was significant.
2-3-2.血中の乳酸濃度
投与60日後のControl群、桑の葉群、タヒボ群、シャンピニオン群及び配合群の血中の乳酸濃度の結果を図4に示した。
図4で見るところのようにControl群と比べて桑の葉群、タヒボ群、シャンピニオン群、配合群の血中の乳酸濃度の低下が認められた。
2-3-2. FIG. 4 shows the results of blood lactate concentration in the Control group, Mulberry leaf group, Tahibo group, Champignon group, and
As seen in FIG. 4, a decrease in blood lactic acid concentration was observed in the mulberry leaf group, the tahibo group, the champignon group, and the combination group as compared with the Control group.
2-3-3.血中のアンモニア濃度
投与60日後のControl群、桑の葉群、タヒボ群、シャンピニオン群及び配合群の血中のアンモニア濃度の結果を図5に示した。
図5で見るところのようにControl群と比べて桑の葉群、タヒボ群、シャンピニオン群の血中のアンモニア濃度低下が認められたし、特に配合群の血中のアンモニア濃度低下が著しかった。
2-3-3. FIG. 5 shows the results of blood ammonia concentrations in the Control group, Mulberry leaf group, Tahibo group, Champignon group, and
As seen in FIG. 5, a decrease in blood ammonia concentration was observed in the mulberry leaf group, the tahibo group, and the champignon group as compared with the Control group, and in particular, the decrease in the blood ammonia concentration in the combination group was significant.
2-3-4.小便による金属元素(銅、鉛、亜鉛、マグネシウム、カドミウム、ナトリウム)の検査結果
2-3-4-1.小便による銅の濃度
投与60日後のControl群、桑の葉群、タヒボ群、シャンピニオン群及び配合群の小便による銅の濃度の結果を図6に示した。
図6で見るところのようにControl群の小便中の銅の濃度と比べて桑の葉群、タヒボ群、シャンピニオン群では別に差がなかった。しかし、配合群では銅濃度の低下が認められた。
2-3-4. Test results of metallic elements (copper, lead, zinc, magnesium, cadmium, sodium) by urine 2-3-4-1. FIG. 6 shows the results of copper concentration due to urine in the Control group, the mulberry leaf group, the tahibo group, the champignon group, and the
As seen in FIG. 6, there was no difference in the mulberry leaf group, the tahibo group, and the champignon group compared to the copper concentration in the urine of the Control group. However, a decrease in copper concentration was observed in the blend group.
2-3-4-2.小便による鉛の濃度
投与60日後のControl群、桑の葉群、タヒボ群、シャンピニオン群及び配合群の小便による鉛の濃度の結果を図7に示した。
図7で見るところのようにControl群の小便中の鉛の濃度と比べる時桑の葉群、タヒボ群、シャンピニオン群で低かったことを分かったし、特に配合群の場合鉛濃度が最も低かった。
2-3-4-2. Lead concentration by urine The results of lead concentration by urine in the Control group, Mulberry leaf group, Tahibo group, Champignon group, and
As shown in FIG. 7, it was found that the mulberry leaf group, the tahibo group, and the champignon group had a lower lead concentration than the control group urine lead concentration, and the lead concentration was particularly low in the combination group.
2-3-4-3.小便による亜鉛の濃度
投与60日後のControl群、桑の葉群、タヒボ群、シャンピニオン群及び配合群の小便による亜鉛の濃度の結果を図8に示した。
図8で見るところのようにControl群の小便中の亜鉛の濃度と比べる時桑の葉群、タヒボ群、シャンピニオン群で低かったことを分かったし、特に配合群の場合亜鉛濃度が最も低かった。
2-3-4-3. FIG. 8 shows the results of zinc concentration due to urine in the Control group, Mulberry leaf group, Tahibo group, Champignon group, and
As shown in FIG. 8, it was found that the mulberry leaf group, the tahibo group, and the champignon group were low in comparison with the zinc concentration in the urine of the Control group, and the zinc concentration was the lowest particularly in the combination group.
2-3-4-4.小便によるカドミウムの濃度
投与60日後のControl群、桑の葉群、タヒボ群、シャンピニオン群及び配合群の小便によるマグネシウムの濃度の結果を図9に示した。
図9で見るところのようにControl群の小便中のカドミウムの濃度と比べる時桑の葉群、タヒボ群、シャンピニオン群で低かったことを分かったし、特に配合群の場合カドミウム濃度が最も低かった。
2-3-4-4. FIG. 9 shows the results of magnesium concentration by urine in the Control group, Mulberry leaf group, Tahibo group, Champignon group, and
As shown in FIG. 9, it was found that the mulberry leaf group, the tahibo group, and the champignon group had a lower cadmium concentration than the cadmium concentration in the urine of the Control group, and the cadmium concentration was the lowest particularly in the combination group.
2-3-4-5.小便によるマグネシウムの濃度
投与60日後のControl群、桑の葉群、タヒボ群、シャンピニオン群及び配合群の小便によるマグネシウムの濃度の結果を図10に示した。
図10で見るところのようにControl群の小便中のマグネシウムの濃度と比べる時桑の葉群、タヒボ群で低かったことを分かったし、特にシャンピニオン群と配合群の場合マグネシウム濃度がさらに低かった。
2-3-4-5. Magnesium concentration by urine FIG. 10 shows the results of magnesium concentration by urine in the Control group, Mulberry leaf group, Tahibo group, Champignon group, and
As shown in FIG. 10, it was found that the mulberry leaf group and the tahibo group were low in comparison with the magnesium concentration in the urine of the Control group, and the magnesium concentration was particularly lower in the champignon group and the combination group.
2-3-4-5.小便によるナトリウムの濃度
投与60日後のControl群、桑の葉群、タヒボ群、シャンピニオン群及び配合群の小便によるナトリウムの濃度の結果を図11に示した。
図11で見るところのようにControl群の小便中のナトリウムの濃度と比べる時桑の葉群、タヒボ群では別に差がなかったが、シャンピニオン群の場合ナトリウム濃度が低かったし、配合群の場合ナトリウム濃度が最も低かった。
2-3-4-5. Concentration of sodium by urine FIG. 11 shows the results of sodium concentration by urine in Control group, Mulberry leaf group, Tahibo group, Champignon group, and
As seen in FIG. 11, there was no difference between the Mulberry leaves group and the Tahitibo group when compared to the sodium concentration in the urine of the Control group, but the sodium concentration was lower in the champignon group and sodium in the combination group. The concentration was the lowest.
以上の実施例で見るところのように本発明は、タヒボ粉末、シャンピニオン粉末及び桑の葉粉末が抗酸化作用など各実施例で単独でも効果があるが、これらを共に投与する場合、相乗効果があることが分かる。 As seen in the above examples, the present invention is effective in each example, such as tahibo powder, champignon powder and mulberry leaf powder, such as antioxidant action, but when these are administered together, there is a synergistic effect. I know that there is.
したがって本発明は、タヒボ粉末20〜50重量部とシャンピニオン粉末20〜50重量部及び桑の葉粉末20〜50重量部を配合して製造されたことを特徴とする健康食品組成物を提供する。一方、シャンピニオン粉末は砂糖黍を搾った後残った残物または豆を搾った後残った残物を、60〜90日間堆肥を生産する段階;前記堆肥にシャンピニオン菌を注入して、30〜50日間培養する段階;前記培養されたシャンピニオンを採取して水で洗滌した後2〜5cm大きさで切断する段階;前記大きさで切断したシャンピニオンを乾燥器に移送して、45〜55℃で8〜12時間乾燥させる段階;及び前記乾燥したシャンピニオンを粉砕機に移送して1.5mmの粉末に粉碎する段階;を経って製造される。 Accordingly, the present invention provides a health food composition produced by blending 20-50 parts by weight of tahibo powder, 20-50 parts by weight of champignon powder, and 20-50 parts by weight of mulberry leaf powder. On the other hand, the champignon powder is a residue produced after squeezing sugar cane or a residue remaining after squeezing beans to produce compost for 60 to 90 days; Culturing; collecting the cultivated champignon, washing it with water and then cutting it in a size of 2-5 cm; transferring the champignon cut in the size to a dryer, and For 12 hours; and the dried champignon is transferred to a pulverizer and ground into 1.5 mm powder.
Claims (1)
前記シャンピニオン粉末は、砂糖黍を搾った後残った残物または豆を搾った後残った残物から60〜90日間で堆肥を生産する段階;
前記堆肥にシャンピニオン菌を注入して30〜50日間培養する段階;
前記培養されたシャンピニオンを採取して、水で洗滌した後2〜5cm大きさで切断する段階;
前記大きさで切断したシャンピニオンを乾燥器に移送して、45〜55℃で8〜12時間乾燥させる段階;及び
前記乾燥したシャンピニオンを粉砕機に移送して、1.5mmの粉末に粉砕する段階;を経て製造されたことを特徴とする健康食品組成物。 It is manufactured by blending 20-50 parts by weight of tahibo powder, 20-50 parts by weight of champignon powder and 20-50 parts by weight of mulberry leaf powder,
The champignon powder includes the steps of producing compost between 60-90 days from the remaining remnants after squeezed remaining remains or beans after squeezing sugar cane;
Injecting champignon into the compost and culturing for 30-50 days;
Collecting the cultured champignon, washing it with water and then cutting it to a size of 2-5 cm;
And transferring the champignon cut in the size of the dryer, 8-12 hours dried step by step at 45 to 55 ° C.; and transferred to a crusher and champignon that the drying and pulverizng to 1.5mm powder A health food composition produced through the steps of:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2008-0069867 | 2008-07-18 | ||
KR1020080069867A KR101017556B1 (en) | 2008-07-18 | 2008-07-18 | Health food compositions included taheebo, champignon and mulberry leaves |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010022359A JP2010022359A (en) | 2010-02-04 |
JP4802251B2 true JP4802251B2 (en) | 2011-10-26 |
Family
ID=41728798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009010890A Expired - Fee Related JP4802251B2 (en) | 2008-07-18 | 2009-01-21 | Health food composition made mainly of tahibo, champignon and mulberry leaves |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4802251B2 (en) |
KR (1) | KR101017556B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102670769A (en) * | 2011-03-18 | 2012-09-19 | 李启辉 | Tea lowering blood pressure and enabling all natural plants to serve as formula and preparation method thereof |
JP6050678B2 (en) * | 2012-12-28 | 2016-12-21 | ポーラ化成工業株式会社 | Skin external preparation for hair |
WO2019013374A1 (en) * | 2017-07-14 | 2019-01-17 | (주)뉴트리바이오텍 | Method for preparing freeze-dried product of taheebo ethanol extract |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02150239A (en) * | 1988-12-01 | 1990-06-08 | Shoichi Shimizu | Confectioneries containing 'tahibo' (tabebuia altisima) |
JPH09252746A (en) * | 1996-03-22 | 1997-09-30 | Nippon Kankyo Yakuhin Kk | Nutrient-supplementing food |
JP2005034117A (en) * | 2003-07-14 | 2005-02-10 | Hokkaido Ekotekkusu Kk | Technique and method for utilization of compost recycled from waste such as food residue for bed (medium) culture of mushroom |
JP2007330124A (en) * | 2006-06-13 | 2007-12-27 | Kenko Tsusho Kk | Health food composition for preventing and ameliorating obesity and lifestyle-related disease |
KR20080092263A (en) * | 2007-04-10 | 2008-10-15 | 김국현 | Cox-2 and inos proteins expression inhibitor |
-
2008
- 2008-07-18 KR KR1020080069867A patent/KR101017556B1/en not_active IP Right Cessation
-
2009
- 2009-01-21 JP JP2009010890A patent/JP4802251B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2010022359A (en) | 2010-02-04 |
KR20100009136A (en) | 2010-01-27 |
KR101017556B1 (en) | 2011-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6185157B2 (en) | Multifunctional composition and method for making and using | |
KR102211027B1 (en) | Natural smell perfect lock and feed composition for companion animal containing the same | |
KR101723206B1 (en) | Pills for health supplement food comprising extracts of protaetia brebitarsis larba and manufacturing method for the same | |
CN102178086B (en) | Feed additive for improving quality and flavor of pork, feed, and preparation method thereof | |
KR101539382B1 (en) | Food composition for improvement of bowel function and relief of constipation | |
KR101357338B1 (en) | A deer feed composition improving the quality of meat and antlers through the high content of sulfur, saponins and unsaturated fatty acid obtained from that deer fed that feed | |
JP4802251B2 (en) | Health food composition made mainly of tahibo, champignon and mulberry leaves | |
KR102014675B1 (en) | Method of producing a granular health funciotnal food | |
KR101895733B1 (en) | Mixed feed for companion animals | |
KR20110014418A (en) | A hot spice | |
CN109315348B (en) | Breeding method of spicy pigs | |
KR101902313B1 (en) | Composition of baby food and nourishing food for pet | |
JP2011037811A (en) | Fat-decreasing composition | |
CN110651895B (en) | Functional food for solving tear stains of pets and preparation method thereof | |
CN106819575A (en) | A kind of feed formula for resisting heat stress of broilers | |
CN107006699A (en) | A kind of meat sheep feed containing Chinese herbal medicine | |
KR20210087284A (en) | Manufacturing method of natural plant sulfur feed for raising sulfur duck | |
KR101645584B1 (en) | Functional fermented soybean lump and traditional Korean sauces produced by the fermented soybean lump | |
CN103636557A (en) | Method for preventing and treating tooth loss or tooth breakage of bamboo rats | |
CN103535575A (en) | Novel formula and production technology of rose pollen tablet product | |
KR20120080793A (en) | Feed composition comprising chestnut and manufacturing method thereof | |
KR102281273B1 (en) | Pet food comprising fermented allium hookeri and method thereof | |
CN108567059B (en) | Pig feed and preparation method thereof | |
CN107125480A (en) | A kind of feed for improving beaver rabbit immunity and preparation method thereof | |
KR101554844B1 (en) | Bean-mixed Filefish Jerky and Producing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090313 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100922 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101005 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101221 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110322 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110509 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110502 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20110602 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110628 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110701 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110726 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110808 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140812 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4802251 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |